Table 4.
Predictors of 12-Month CILC at the Participant Level
| Predictor | Participants, No. | Univariate Analysis | Multivariable Modelb | ||
|---|---|---|---|---|---|
| CILC, No. (%) | P Valuea | RR (95% CI) | P Value | ||
| Study arm | |||||
| IRC treatment | 60 | 37 (62) | <.001 | 2.22 (1.49–3.29) | <.001 |
| AM arm | 60 | 18 (30) | 1 | ||
| Clinical site | |||||
| S.E.G. site | 71 | 39 (55) | .02 | 1.47 (1.03–2.09) | .03 |
| Other 5 sites | 49 | 16 (33) | 1 | ||
| Age, y | |||||
| 25–49 | 60 | 25 (42) | .36 | … | … |
| 50–78 | 60 | 30 (50) | … | ||
| Sex | |||||
| Male | 112 | 51 (46) | … | … | |
| Female | 8 | 4 (50) | >.99 | … | |
| Race | |||||
| White | 92 | 42 (46) | .94 | … | … |
| Nonwhite | 28 | 13 (46) | … | ||
| Ethnicity | |||||
| Hispanic or Latino | 22 | 14 (64) | .07 | … | … |
| Non-Hispanic or non-Latino | 97 | 41 (42) | … | ||
| Nadir CD4 cell count, cells/µL | |||||
| ≥200 | 78 | 35 (45) | .77 | … | … |
| <200 | 42 | 20 (48) | … | ||
| AIDS diagnosis | |||||
| Yes | 39 | 16 (41) | .46 | … | … |
| No | 81 | 39 (48) | … | ||
| History of HSIL | |||||
| Yes | 58 | 27 (47) | .88 | … | … |
| No | 62 | 28 (45) | … | ||
| Prior treatment for HSIL | |||||
| Yes | 45 | 23 (51) | .37 | … | … |
| No | 75 | 32 (42) | … | ||
| ART | |||||
| Yes | 108 | 54 (50) | .006 | 4.95 (0.77–31.60) | .09 |
| No | 12 | 1 (8) | 1 | ||
| Baseline CD4 cells/µL | |||||
| ≥500 | 93 | 41 (44) | .48 | … | … |
| <500 | 27 | 14 (52) | … | ||
| Baseline CD8 cells/µL | |||||
| ≥847 (median) | 57 | 26 (46) | .85 | … | … |
| <847 | 57 | 27 (47) | … | ||
| Detectable HIV viral load | |||||
| No | 77 | 36 (47) | .77 | … | … |
| Yes | 41 | 18 (44) | … | ||
| No. of index lesions | |||||
| 1 | 73 | 42 (58) | .001 | 1.96 (1.22–3.10) | .005 |
| 2–3 | 47 | 13 (28) | 1 | ||
| Sum of greatest diameters, mm | |||||
| 0 to <9 | 61 | 33 (54) | .06 | … | … |
| ≥9 | 59 | 22 (37) | … | ||
| Total | 120 | 55 (46) | … | ||
Abbreviations: AM, active monitoring; ART, antiretroviral therapy; CI, confidence interval; CILC, complete index lesion clearance; HIV, human immunodeficiency; HSIL, high-grade squamous intraepithelial lesion; IRC, infrared coagulation; RR, relative risk.
a P values determined with χ2 test.
bVariables significant at P < .10 in univariate analyses were considered in the multivariable generalized estimating equations binary model for RR, which adjusted for clinical site and accounted for clustering of lesions within participant; the final multivariable model included only variables that were significant at P < .10 after adjustment for other variables in the model. Ethnicity and sum of greatest diameters did not meet inclusion criterion after adjustment for treatment, site, ART, and number of index lesions.